Doxazosin Tablet
Product Images NDC 68788-8422

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 4 technical images submitted to the FDA as part of the official labeling for Doxazosin (NDC 68788-8422). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Preferred Pharmaceuticals Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Doxazosin Tablets Usp 2mg (E046e0b7 F510 4318 9884 034d683864d4 00)

Doxazosin Tablets Usp 2mg (E046e0b7 F510 4318 9884 034d683864d4 00)
Doxazosin Tablets USP 2mg is a generic drug used for treating high blood pressure and is equivalent to Cardura. Each tablet contains doxazosin mesylate, measuring 2mg in power. The drug should be stored within the temperature range of 20°C to 25°C, with an excursion permitted to 15°C to 30°C. The tablets are of capsule shape, white, scored and carry the label APO 094. The drug should be used according to the physician's instructions, and it is essential to keep it away from the reach of children. Important details such as the product number (NDC), expiration date, lot#, and batch# are required for inventory and record-keeping purposes. Federal law restricts the transfer of the drug to the patient for whom it was prescribed.*
FDA Label Image

Doxazosin-structure.jpg (Doxazosin Structure)

FDA Label Image

Figure1.jpg (Figure1)

Figure1.jpg (Figure1)
This appears to be a table or graph displaying data on the mean change in total symptom score and increase in maximum urinary flow score from baseline, over a duration of treatment in weeks. The asterisks indicate statistical significance, with *p <0.05 meaning the data is significantly different from placebo, and +p <0.05 meaning the data is significantly different from baseline. Doxazosin titration to a maximum of 8 mg is also mentioned.*
FDA Label Image

Table3.jpg (Table3)

Table3.jpg (Table3)
This is a summary of effectiveness data in placebo-controlled clinical trials for doxazosin in the treatment of BPH (Benign Prostatic Hyperplasia). The data includes the maximum flow rate and symptom score (measured in mL/sec and on a scale of 0-30) and mean baseline change for placebo and doxazosin groups across different titration regimens and study durations. The modified Boyarsky questionnaire (range 7-39) was used in Study 2. The asterisks indicate additional information, such as the number of patients receiving a dose of 8mg doxazosin and the significance of mean change compared to placebo.*

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.